Nutriband Inc., a pharmaceutical technology company, is developing a novel approach to transdermal pain management through its AVERSA™ drug delivery platform. In a recent BioMedWire Podcast interview, CEO Gareth Sheridan outlined the company's strategy to address significant challenges in opioid therapy delivery.
The fentanyl patch market has experienced a severe contraction, dropping from $4 billion in 2016 to less than $1 billion today. This decline stems primarily from growing concerns about opioid abuse and the associated stigma surrounding these medications. Despite this reduction, the patient population requiring pain management remains substantial.
Nutriband's AVERSA™ platform is designed to tackle these challenges by creating opioid patches that are difficult to manipulate for non-medical use. The technology aims to restore prescriber and payer confidence by providing a safer alternative to traditional transdermal opioid treatments.
The innovation addresses a critical gap in pain management, where liability concerns and abuse potential have limited patient access to effective medications. By developing a more secure delivery mechanism, Nutriband seeks to help healthcare providers continue offering necessary pain therapies while mitigating potential misuse risks.
As the healthcare industry continues to grapple with the complex challenges of pain management and opioid safety, Nutriband's approach represents a potential breakthrough in developing more responsible pharmaceutical solutions.
